Cargando…
Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders
Interstitial lung disease (ILD) has been recognized as a frequent manifestation associated with a substantial morbidity and mortality burden in patients with autoimmune rheumatic disorders. Serum autoantibodies are considered good biomarkers for identifying several subsets or specific phenotypes of...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320553/ https://www.ncbi.nlm.nih.gov/pubmed/34377160 http://dx.doi.org/10.1177/1759720X211032457 |
_version_ | 1783730665528754176 |
---|---|
author | Kuwana, Masataka Gil-Vila, Albert Selva-O’Callaghan, Albert |
author_facet | Kuwana, Masataka Gil-Vila, Albert Selva-O’Callaghan, Albert |
author_sort | Kuwana, Masataka |
collection | PubMed |
description | Interstitial lung disease (ILD) has been recognized as a frequent manifestation associated with a substantial morbidity and mortality burden in patients with autoimmune rheumatic disorders. Serum autoantibodies are considered good biomarkers for identifying several subsets or specific phenotypes of ILD involvement in these patients. This review features the role of several autoantibodies as a diagnostic and prognostic biomarker linked to the presence ILD and specific ILD phenotypes in autoimmune rheumatic disorders. The case of the diverse antisynthetase antibodies in the antisynthease syndrome or the anti-melanoma differentiation-associated 5 protein (MDA5) antibodies as a marker of a severe condition such as rapidly progressive ILD in patients with clinically amyopathic dermatomyositis are some of the associations herein reported in the group of myositis spectrum disorders. Specific autoantibodies such as the well-known anti-topoisomerase I (anti-Scl70) or the anti-Th/To, anti-U11/U12 ribonucleoprotein, and anti-eukaryotic initiation factor 2B (eIF2B) antibodies seems to be specifically linked to ILD in patients with systemic sclerosis. Overlap syndromes between systemic sclerosis and myositis, also have good ILD biomarkers, which are the anti-PM/Scl and anti-Ku autoantibodies. Lastly, other not so often reported disorders as being associated with ILD but recently most recognized as is the case of rheumatoid arthritis associated ILD or entities herein included in the miscellaneous disorders section, which include anti-neutrophil cytoplasmic antibody-associated interstitial lung disease, Sjögren’s syndrome or the mixed connective tissue disease, are also discussed. |
format | Online Article Text |
id | pubmed-8320553 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-83205532021-08-09 Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders Kuwana, Masataka Gil-Vila, Albert Selva-O’Callaghan, Albert Ther Adv Musculoskelet Dis Interstitial Lung Disease in Autoimmune Rheumatic Disorders Interstitial lung disease (ILD) has been recognized as a frequent manifestation associated with a substantial morbidity and mortality burden in patients with autoimmune rheumatic disorders. Serum autoantibodies are considered good biomarkers for identifying several subsets or specific phenotypes of ILD involvement in these patients. This review features the role of several autoantibodies as a diagnostic and prognostic biomarker linked to the presence ILD and specific ILD phenotypes in autoimmune rheumatic disorders. The case of the diverse antisynthetase antibodies in the antisynthease syndrome or the anti-melanoma differentiation-associated 5 protein (MDA5) antibodies as a marker of a severe condition such as rapidly progressive ILD in patients with clinically amyopathic dermatomyositis are some of the associations herein reported in the group of myositis spectrum disorders. Specific autoantibodies such as the well-known anti-topoisomerase I (anti-Scl70) or the anti-Th/To, anti-U11/U12 ribonucleoprotein, and anti-eukaryotic initiation factor 2B (eIF2B) antibodies seems to be specifically linked to ILD in patients with systemic sclerosis. Overlap syndromes between systemic sclerosis and myositis, also have good ILD biomarkers, which are the anti-PM/Scl and anti-Ku autoantibodies. Lastly, other not so often reported disorders as being associated with ILD but recently most recognized as is the case of rheumatoid arthritis associated ILD or entities herein included in the miscellaneous disorders section, which include anti-neutrophil cytoplasmic antibody-associated interstitial lung disease, Sjögren’s syndrome or the mixed connective tissue disease, are also discussed. SAGE Publications 2021-07-27 /pmc/articles/PMC8320553/ /pubmed/34377160 http://dx.doi.org/10.1177/1759720X211032457 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Interstitial Lung Disease in Autoimmune Rheumatic Disorders Kuwana, Masataka Gil-Vila, Albert Selva-O’Callaghan, Albert Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders |
title | Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders |
title_full | Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders |
title_fullStr | Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders |
title_full_unstemmed | Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders |
title_short | Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders |
title_sort | role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders |
topic | Interstitial Lung Disease in Autoimmune Rheumatic Disorders |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320553/ https://www.ncbi.nlm.nih.gov/pubmed/34377160 http://dx.doi.org/10.1177/1759720X211032457 |
work_keys_str_mv | AT kuwanamasataka roleofautoantibodiesinthediagnosisandprognosisofinterstitiallungdiseaseinautoimmunerheumaticdisorders AT gilvilaalbert roleofautoantibodiesinthediagnosisandprognosisofinterstitiallungdiseaseinautoimmunerheumaticdisorders AT selvaocallaghanalbert roleofautoantibodiesinthediagnosisandprognosisofinterstitiallungdiseaseinautoimmunerheumaticdisorders |